Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches (vol 106, pg 70, 2017)

被引：1
|
作者：
Remon, J. [1 ]
Pardo, N. [1 ]
Martinez-Marti, A. [1 ]
Cedres, S. [1 ]
Navarro, A. [1 ]
Martinez de Castro, A. M. [1 ]
Felip, E. [1 ]
机构：
[1] Hosp Valle De Hebron, Dept Med Oncol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
来源：
LUNG CANCER | 2018年 / 117卷
关键词：
D O I：
10.1016/j.lungcan.2017.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [1] Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches
    Remon, J.
    Pardo, N.
    Martinez-Marti, A.
    Cedres, S.
    Navarro, A.
    Martinez de Castro, A. M.
    Felip, E.
    [J]. LUNG CANCER, 2017, 106 : 70 - 75
  • [2] Current status of immune-checkpoint inhibitors in the first-line treatment of metastatic non-small cell lung cancer
    Tanaka, Kentaro
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 32 - 32
  • [3] First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
    Huang, Zhangfeng
    Su, Wenhao
    Lu, Tong
    Wang, Yuanyong
    Dong, Yanting
    Qin, Yi
    Liu, Dahai
    Sun, Lili
    Jiao, Wenjie
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [4] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
    Remon, Jordi
    Besse, Benjamin
    [J]. CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
  • [5] Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first-line treatment for advanced non-small cell lung cancer
    Rizzo, Alessandro
    [J]. THORACIC CANCER, 2022, 13 (04) : 656 - 656
  • [6] First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions
    Christoph Jakob Ackermann
    Helen Adderley
    Ana Ortega-Franco
    Adeel Khan
    Martin Reck
    Raffaele Califano
    [J]. Drugs, 2020, 80 : 1783 - 1797
  • [7] First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions
    Ackermann, Christoph Jakob
    Adderley, Helen
    Ortega-Franco, Ana
    Khan, Adeel
    Reck, Martin
    Califano, Raffaele
    [J]. DRUGS, 2020, 80 (17) : 1783 - 1797
  • [8] Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
    Ryu, Rachel
    Ward, Kristina E.
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
  • [9] Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer
    Kehl, Kenneth L.
    Greenwald, Scott
    Chamoun, Nassib G.
    Manberg, Paul J.
    Schrag, Deborah
    [J]. JAMA NETWORK OPEN, 2021, 4 (05)
  • [10] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
    Lee, Young Joo
    Kim, Heung Tae
    Han, Ji-Youn
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Sung, Ji-Hyun
    Lee, Jin Soo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 361 - 368
12345